Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BCRX
BCRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BCRX News
BioCryst Pharmaceuticals Faces Dismal Outlook
Feb 07 2026
Yahoo Finance
Astria Therapeutics to be Sold to BioCryst for $8.55 per Share
Jan 07 2026
PRnewswire
BioCryst Grants 18,300 RSUs to New Employee as Inducement
Jan 06 2026
Globenewswire
BioCryst to Present at J.P. Morgan Healthcare Conference on January 12, 2026
Jan 06 2026
Globenewswire
BioCryst Receives FDA Approval for Oral Medication to Treat Rare Swelling Disorder in Children
Dec 12 2025
Benzinga
BioCryst Receives FDA Approval for ORLADEYO Oral Therapy for Pediatric HAE Patients
Dec 12 2025
Globenewswire
BioCryst Receives FDA Approval for ORLADEYO Oral Therapy for Pediatric HAE Patients
Dec 12 2025
Newsfilter
FDA Grants Approval for Orladeyo Oral Pellets for Pediatric Patients with Hereditary Angioedema
Dec 12 2025
NASDAQ.COM
BioCryst's Orladeyo Oral Pellets Approved by FDA for HAE Patients Aged 2 to Under 12
Dec 12 2025
NASDAQ.COM
BioCryst Receives FDA Approval for Orladeyo Oral Pellets
Dec 12 2025
SeekingAlpha
BioCryst Receives HSR Act Termination for Astria Acquisition
Dec 03 2025
Globenewswire
BioCryst Receives Early Termination for Astria Acquisition Under HSR Act
Dec 03 2025
Newsfilter
BioCryst Data Reveals Significant Psychosocial Impact of HAE on Children and Their Caregivers
Nov 30 2025
Yahoo Finance
Biotech Stocks Await FDA Verdict in December 2025
Nov 27 2025
NASDAQ.COM
Reasons Behind Dyne Therapeutics Stock Surge This Week
Nov 21 2025
NASDAQ.COM
Needham Keeps Buy Rating on BioCryst Pharma, Reduces Price Target to $18
Nov 04 2025
Benzinga
Show More News
